Dr. Antonio Calles 🫁🚭· @Tony_Calles · X·· 4 小时前评分70
正文 · 原文
HERON-Lung01: Ruzaltatug rezetecan (SHR-A2009), antiHER3 ADC, showed increased efficacy in terms of ORR and PFS, but OS not mature yet compared to pt-based chemotherapy. Significant toxicities. Not a SoC yet to me. #ESMO26 #LCSM
27 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA13按 Proffered paper 1: Breast cancer, early and advanced stage 对上
Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer (BC): A randomized, phase 3 study (HORIZON-Breast06)
https://esmocongress.esmo.org来源：Dr. Antonio Calles 🫁🚭 · x.com